QRG Capital Management Inc. Trims Stock Holdings in Novo Nordisk A/S $NVO

QRG Capital Management Inc. decreased its position in Novo Nordisk A/S (NYSE:NVO) by 14.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 110,286 shares of the company’s stock after selling 19,045 shares during the quarter. QRG Capital Management Inc.’s holdings in Novo Nordisk A/S were worth $5,611,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Revolve Wealth Partners LLC lifted its position in Novo Nordisk A/S by 8.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock valued at $214,000 after acquiring an additional 200 shares during the period. AQR Capital Management LLC boosted its stake in Novo Nordisk A/S by 21.0% during the first quarter. AQR Capital Management LLC now owns 62,099 shares of the company’s stock worth $4,312,000 after acquiring an additional 10,758 shares in the last quarter. Sivia Capital Partners LLC grew its holdings in Novo Nordisk A/S by 18.2% in the second quarter. Sivia Capital Partners LLC now owns 10,320 shares of the company’s stock worth $712,000 after purchasing an additional 1,587 shares during the period. Invesco Ltd. increased its stake in shares of Novo Nordisk A/S by 26.3% during the second quarter. Invesco Ltd. now owns 419,691 shares of the company’s stock valued at $28,967,000 after purchasing an additional 87,467 shares in the last quarter. Finally, Gamco Investors INC. ET AL bought a new position in shares of Novo Nordisk A/S during the second quarter valued at approximately $314,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Up 2.1%

Shares of NYSE NVO opened at $45.82 on Thursday. The firm’s 50 day moving average price is $38.57 and its 200-day moving average price is $47.03. Novo Nordisk A/S has a 52-week low of $35.12 and a 52-week high of $81.44. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.57 and a current ratio of 0.80. The company has a market cap of $204.57 billion, a PE ratio of 13.20, a P/E/G ratio of 10.65 and a beta of 0.77.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. The company had revenue of $10.85 billion during the quarter. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. On average, equities research analysts expect that Novo Nordisk A/S will post 3.34 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on NVO shares. Morgan Stanley raised Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 price target on the stock in a research report on Tuesday, March 3rd. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $41.00 price objective (down from $63.00) on shares of Novo Nordisk A/S in a research report on Monday, March 2nd. CICC Research initiated coverage on Novo Nordisk A/S in a research note on Friday, January 9th. They set an “outperform” rating and a $73.50 price objective for the company. Nordea Equity Research downgraded Novo Nordisk A/S to a “hold” rating in a report on Tuesday, February 24th. Finally, JPMorgan Chase & Co. reissued a “neutral” rating on shares of Novo Nordisk A/S in a research note on Tuesday, February 24th. Four research analysts have rated the stock with a Buy rating, eighteen have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $65.56.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Q1 beat and guidance raise driven by Wegovy pill: Management reported stronger?than?expected demand for the new Wegovy oral pill, lifted sales and raised FY?2026 guidance, prompting the stock rally. Reuters: Q1 profit beats
• Positive Sentiment: Wegovy uptake scale: Total Wegovy prescriptions surpassed ~2 million since launch, indicating strong volume growth and potential to offset near?term pricing headwinds. WSJ: Wegovy lifts guidance
• Positive Sentiment: Management open to M&A and broader pipeline build: CEO Mike Doustdar said Novo is actively seeking deals to strengthen its pipeline, which investors view as a sign management is pursuing growth options beyond organic product rollouts. CNBC: CEO on deals
• Positive Sentiment: Share repurchase program in place: Novo has an active share buyback program (part of a DKK15bn program) which supports per?share metrics and can provide buy?side demand. GlobeNewswire: Buyback
• Neutral Sentiment: Mixed analyst reads: Some analysts call the quarter an inflection/turnaround (beat + volume), others note mixed metrics and are cautious; the market is debating whether current pessimism already prices future upside. Seeking Alpha: Mixed Q1
• Negative Sentiment: Pricing pressure, margin compression and accounting noise: U.S. pricing pressure and a one?off 340B benefit exclusion reduced adjusted EPS/revenue in the quarter and led management to give cautious near?term guidance despite strong volumes. Seeking Alpha: Misread Q1
• Negative Sentiment: Intense competitive risk: A price war with Eli Lilly and potential generics (though China generic Ozempic may be delayed) remain major downside risks to pricing and long?term margins. Reuters: Price war test

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.